XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 32.38

-0.3%

1:27 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (7269)	9/22/1998 9:25:00 PM
From: Robert K.	Read Replies (1) of 17367

I am well aware of the antiangiogenic possibilites to some extent. You know bpi21 and bpi42 (iprex) both have antiangiogenic effects. Of course there are many reasons bpi21 might be useful in cancer besides anti angio. Mike -I really dont think you know what you got on your fishing line. And I am not talking anti-angio potential either. I wonder what would happen should bpi21 get approved fasttrack? Hmmmm. But thats speculation at this point. All IMO. all disclaimers apply

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next